RAS blockade in experimental renal transplantation. Benefits and limitations

Current Drug Targets - Cardiovascular and Haematological Disorders

Volumn 3, Issue 1, 2003, Pages 73-79

  Smit van Oosten, Annemieke ^a   Stegeman, Coen A ^a   van Goor, Harry ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

ACE inhibition; Chronic renal transplant failure; Fisher to Lewis model; Human; RAS; Rat; Transplantation

Indexed keywords

2 ETHYL 5,7 DIMETHYL 3 [4 [2 (2H TETRAZOL 5 YL)PHENYL]BENZYL]IMIDAZO[4,5 B]PYRIDINE; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN I; ANTIHYPERTENSIVE AGENT; ARGININE; CALCIUM CHANNEL BLOCKING AGENT; CHYMASE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR; FIBROBLAST GROWTH FACTOR; GLYCERYL TRINITRATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; L 158819; LACIDIPINE; LISINOPRIL; LOSARTAN; MOLSIDOMINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR; TETRAHYDROBIOPTERIN; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ARTERY INTIMA PROLIFERATION; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY FAILURE; DRUG EFFICACY; DRUG POTENTIATION; GENETIC RISK; GENOTYPE; GLOMERULOSCLEROSIS; HORMONE ACTION; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ARTERY STENOSIS; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; NONHUMAN; PATHOGENESIS; PROTEINURIA; RAT; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DISEASE MODELS, ANIMAL; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; RENIN-ANGIOTENSIN SYSTEM;

EID: 0037371040     PISSN: 15680061     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568006033337258     Document Type: Review

References (62)

1. Denton, M.D., Magee, C.C., Sayegh, M.H. Immunosuppressive strategies in transplantation. Lancet, 1999, 27, 1083-1091.
2. Kreis, H.A., Ponticelli, C. Causes of late renal allograft loss: chronic allograft dysfunction, death, and other factors. Transplantation, 2001, 71, SS5-9.
3. Paul, L.C. Chronic allograft nephropathy: An update. Kidney Int., 1999, 56, 783-793.
4. Kasiske, B.L., Vazquez, M.A., Harmon, W.E., Brown, R.S., Danovitch, G.M., Gaston, R.S., Roth, D., Scandling, J.D., Singer, G.G. Recommendations for the outpatient surveillance of renal transplant recipients. J. Am. Soc. Nephrol., 2000, 11, S1-86.
5. Fellstrom, B. Risk factors for and management of post-transplantation cardiovascular disease. BioDrugs, 2001, 15, 261-278.
6. Almond, P.S., Matas, A.J., Gillingham, K., Dunn, D.L., Payne, W.D., Gores, P., Gruessner, R., Najarian, J.S. Predictors of chronic rejection in renal transplant recipients. Transplant. Proc., 1993, 25, 936.
7. Paul, L.C. Immunologic risk factors for chronic renal allograft dysfunction. Transplantation, 2001, 71, SS17-23.
8. Szabo, A., Heemann, U. Ischemia reperfusion injury and chronic allograft rejection. Transplant. Proc., 1998, 30, 4281-4284.
9. Dimeny, E., Tufveson, G, Lithell, H., Larsson, E., Siegbahn, A., Fellstrom, B. The influence of pretransplant lipoprotein abnormalities on the early results of renal transplantation. Eur. J. Clin. Invest., 1993, 23, 572-579.
10. Brenner, B.M., Cohen, R.A., Milford, E.L. In renal transplantation, one size may not fit all. J. Am. Soc. Nephrol., 1992, 3, 162-169.
11. Halloran, P.F., Melk, A., Barth, C. Rethinking chronic allograft nephropathy: the concept of accelerated senescence. J. Am. Soc. Nephrol., 1999, 10, 167-181.
12. Terasaki, P.I., Koyama, H., Cecka, J.M., Gjertson, D.W. The hyperfiltration hypothesis in human renal transplantation. Transplantation, 1994, 57, 1450-1454.
13. Pratschke, J., Wilhelm, M.J., Laskowski, I., Kusaka, M., Beato, F., Tullius, S.G, Neuhaus, P., Hancock, W.W., Tilney, N.L. Influence of donor brain death on chronic rejection of renal transplants in rats. J. Am. Soc. Nephrol., 2001, 12, 2474-2481.
14. Pratschke, J., Wilhelm, M.J., Laskowski, I., Kusaka, M., Paz, D., Tullius, S.G., Neuhaus, P., Hancock, W.W., Tilney, N.L. The influence of donor brain death on long-term function of renal allotransplants in rats. Transplant. Proc., 2001, 33, 693-694.
15. Pratschke, J., Wilhelm, M.J., Kusaka, M., Hancock, W.W., Tilney, N.L. Acute rejection of rat renal allografts is accelerated by donor brain death. Transplant. Proc., 1999, 31, 874-875.
16. Tullius, S.G, Heemann, U.W., Azuma, H., Hancock, W.W., Tilney, N.L. Alloantigen-independent factors lead to signs of chronic rejection in long-term kidney isografts. Transpl. Int., 1994, 7, S306-307.
17. Tullius, S.G., Heemann, U., Hancock, W.W., Azuma, H., Tilney, N.L. Long-term kidney isografts develop functional and morphologic changes that mimic those of chronic allograft rejection. Ann. Surg., 1994, 220, 425-432.
18. White, E., Hildemann, W.H., Mullen, Y. Chronic kidney allograft reactions in rats. Transplantation, 1969, 8, 602-617.
19. Diamond, J.R., Tilney, N.L., Frye, J., Ding, G, McElroy, J., Pesek-Diamond, I., Yang, H. Progressive albuminuria and glomerulosclerosis in a rat model of chronic renal allograft rejection. Transplantation, 1992, 54, 710-716.
20. Naftilan, A.J., Pratt, R.E., Dzau, V.J. Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. J. Clin. Invest., 1989, 83, 1419-1424.
21. Gibbons, G.H., Pratt, R.E., Dzau, V.J. Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J. Clin. Invest., 1992, 90, 456-461.
22. Kagami, S., Border, W.A., Miller, D.E., Noble, N.A. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J. Clin. Invest., 1994, 93, 2431-2437.
23. Fogo, A.B. The role of angiotensin II and plasminogen activator inhibitor-1 in progressive glomerulosclerosis. Am. J. Kidney Dis., 2000, 35, 179-188.
24. Zhuo, J.L. Renomedullary interstitial cells: a target for endocrine and paracrine actions of vasoactive peptides in the renal medulla. Clin. Exp. Pharmacol. Physiol., 2000, 27, 465-473.
25. Klahr, S., Morrissey, J.J. The role of vasoactive compounds, growth factors and cytokines in the progression of renal disease. Kidney Int. Suppl., 2000, 75, S7-14.
26. Taal, M.W., Brenner, B.M. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int., 2000, 57, 1803-1817.
27. De Gasparo, M., Catt, K.J., Inagami, T., Wright, J.W., Unger, T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev., 2000, 52, 415-472.
28. Jafar, T.H., Stark, P.C., Schmid, C.H., Landa, M., Maschio, G, Marcantoni, C., De Jong, P.E., De Zeeuw, D., Shahinfar, S., Ruggenenti, P., Remuzzi, G., Levey, A.S. Proteinuria as a modifiable risk factor for the. progression of non-diabetic renal disease. Kidney Int., 2001, 60, 1131-1140.
29. Veelken, R., Delles, C., Hilgers, K.F., Schmieder, R.E. Outcome survey in unselected hypertensive patients with type 2 diabetes mellitus: effects of ACE inhibition. Am. J. Hypertens., 2001, 14, 672-678.
30. Jafar, T.H., Schmid, C.H., Landa, M., Giatras, I., Toto, R., Remuzzi, G., Maschio, G, Brenner, B.M., Kamper, A., Zucchelli, P., Becker, G., Himmelmann, A., Bannister, K., Landais, P., Shahinfar, S., De Jong, P.E., De Zeeuw, D., Lau, J., Levey, A.S. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann. Intern. Med., 2001, 135, 73-87.
31. Parving, H.H., Hommel, E., Jensen, B.R., Hansen, H.P. Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int., 2001, 60, 228-234.
32. Ecder, T., Edelstein, C.L., Fick-Brosnahan, G.M., Johnson, A.M., Chapman, A.B., Gabow, P.A., Schrier, R.W. Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease. Am. J. Nephrol., 2001, 21, 98-103.
33. Perna, A., Ruggenenti, P., Testa, A., Spoto, B., Benini, R., Misefari, V., Remuzzi, G., Zoccali, C. ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies. Kidney Int., 2000, 57, 274-281.
34. Hollenberg, N.K. Implications of species difference for clinical investigation: studies on the renin-angiotensin system. Hypertension, 2000, 35, 150-154.
35. Akasu, M., Urata, H., Kinoshita, A., Sasaguri, M., Ideishi, M., Arakawa, K. Differences in tissue angiotensin II-forming pathways by species and organs in vitro. Hypertension, 1998, 32, 514-520.
36. Lewis, J.B., Helderman, J.H. Is it time for ACE inhibitors in chronic allograft nephropathy? Am. J. Kidney Dis., 2000, 35, 154-156.
37. Stigant, C.E., Cohen, J., Vivera, M., Zaltzman, J.S. ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy. Am. J. Kidney Dis., 2000, 35, 58-63.
38. Fervenza, F.C., Lafayette, R.A., Alfrey, E.J., Petersen, J. Renal artery stenosis in kidney transplants. Am. J. Kidney Dis., 1998, 31, 142-148.
39. Hausberg, M., Barenbrock, M., Hohage, H., Muller, S., Heidenreich, S., Rahn, K.H. ACE inhibitor versus beta-blocker for the treatment of hypertension in renal allograft recipients. Hypertension, 1999, 33, 862-868.
40. Campistol, J.M., Inigo, P., Jimenez, W., Lario, S., Clesca, P.H., Oppenheimer, F., Rivera, F. Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy. Kidney Int., 1999, 56, 714-719.
41. Cieciura, T., Senatorski, G, Rell, K., Baczkowska, T., Paczek, L., Gradowska, L., Foroncewicz, B., Mucha, K., Gaciong, Z. Influence of angiotensin-converting enzyme inhibitor treatment of the carotid artery intima-media complex in renal allograft recipients. Transplant. Proc., 2000, 32, 1335-1336.
42. Klingbeil, A.U., Muller, H.J., Delles, C., Fleischmann, E., Schmieder, R.E. Regression of left ventricular hypertrophy by AT1 receptor blockade in renal transplant recipients. Am. J. Hypertens., 2000, 13, 1295-1300.
43. Danovitch, G.M. Can ACE inhibitors prevent chronic allograft failure? Am. J. Kidney Dis., 2001, 37, 866-870.
44. Amuchastegui, S.C., Azzollini, N., Mister, M., Pezzotta, A., Perico, N., Remuzzi, G. Chronic allograft nephropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism. J. Am. Soc. Nephrol., 1998, 9, 1948-1955.
45. Benediktsson, H., Chea, R., Davidoff, A., Paul, L.C. Antihypertensive drug treatment in chronic renal allograft rejection in the rat. Effect on structure and function. Transplantation, 1996, 62, 1634-1642.
46. Szabo, A., Lutz, J., Schleimer, K., Antus, B., Hamar, P., Philipp, T., Heemann, U. Effect of angiotensin-converting enzyme inhibition on growth factor mRNA in chronic renal allograft rejection in the rat. Kidney Int., 2000, 57, 982-991.
47. Mackenzie, H.S., Ziai, F., Nagano, H., Azuma, H., Troy, J.L., Rennke, H.G, Tilney, N.L., Brenner, B.M. Candesartan cilexetil reduces chronic renal allograft injury in Fisher- ->Lewis rats. J. Hypertens. Suppl., 1997, 15, S21-25.
48. Smit-van Oosten, A., Navis, G, Stegeman, C.A., Joles, J.A., Klok, P.A., Kuipers, F., Tiebosch, A.T., Van Goor, H. Chronic blockade of angiotensin II action prevents glomerulosclerosis, but induces graft vasculopathy in experimental kidney transplantation. J. Pathol., 2001, 194, 122-129.
49. Smit-van Oosten, A., Henning, R.H., Van Goor, H. Strain differences in angiotensin-converting enzyme and angiotensin II type I receptor expression. Possible implications for experimental chronic renal transplant failure. JRAAS., 2002, 3, 46-53.
50. Challah, M., Villard, E., Philippe, M., Ribadeau-Dumas, A., Giraudeau, B., Janiak, P., Vilaine, J.P., Soubrier, F., Michel, J.B. Angiotensin I-converting enzyme genotype influences arterial response to injury in normotensive rats. Arterioscler. Thromb. Vasc. Biol., 1998, 18, 235-243.
51. Kreutz, R., Hubner, N., Ganten, D., Lindpaintner, K. Genetic linkage of the ACE gene to plasma angiotensin-converting enzyme activity but not to blood pressure. A quantitative trait locus confers identical complex phenotypes in human and rat hypertension. Circulation, 1995, 92, 2381-2384.
52. Barocci, S., Ginevri, F., Valente, U., Torre, F., Gusmano, R., Nocera, A. Correlation between angiotensin-converting enzyme gene insertion/deletion polymorphism and kidney graft long-term outcome in pediatric recipients: a single-center analysis. Transplantation, 1999, 67, 534-538.
53. Abdi, R., Tran, T.B., Zee, R., Brenner, B.M., Milford, E.L. Angiotensin gene polymorphism as a determinant of posttransplantation renal dysfunction and hypertension. Transplantation, 2001, 72, 726-729.
54. Ritz, E., Schomig, M., Wagner, J. Counteracting progression of renal disease: A look into the future. Kidney Int. Suppl., 2000, 75, S71-76.
55. Noris, M., Azzollini, N., Pezzotta, A., Mister, M., Benigni, A., Marchetti, G., Gagliardini, E., Perico, N., Remuzzi, G. Combined treatment with mycophenolate mofetil and an angiotensin II receptor antagonist fully protects from chronic rejection in a rat model of renal allograft. J. Am. Soc. Nephrol., 2001, 12, 1937-1946.
56. Barton, M., Luscher, T.F. Endothelin antagonists for hypertension and renal disease. Curr. Opin. Nephrol. Hypertens., 1999, 8, 549-556.
57. Blezer, E.L., Nicolay, K., Goldschmeding, R., Jansen, G.H., Koomans, H.A., Rabelink, T.J., Joles, J.A. Early-onset but not late-onset endothelin-A-receptor blockade can modulate hypertension, cerebral edema, and proteinuria in stroke-prone hypertensive rats. Hypertension, 1999, 33, 137-144.
58. Verhagen, A.M., Rabelink, T.J., Braam, B., Opgenorth, T.J., Grone, H.J., Koomans, H.A., Joles, J.A. Endothelin A receptor blockade alleviates hypertension and renal lesions associated with chronic nitric oxide synthase inhibition. J. Am. Soc. Nephrol., 1998, 9, 755-762.
59. Braun, C., Conzelmann, T., Vetter, S., Schaub, M., Back, W.E., Yard, B., Kirchengast, M., Tullius, S.G, Schnulle, P., Van der Woude, F.J., Rohmeiss, P. Prevention of chronic renal allograft rejection in rats with an oral endothelin A receptor antagonist. Transplantation, 1999, 68, 739-746.
60. Orth, S.R., Odoni, G., Amann, K., Strzelczyk, P., Raschack, M., Ritz, E. The ET(A) receptor blocker LU 135252 prevents chronic transplant nephropathy in the "Fisher to Lewis" model. J. Am. Soc. Nephrol., 1999, 10, 387-391.
61. Minamoto, K., Pinsky, D.J., Fujita, T., Naka, Y. Timing of nitric oxide donor supplementation determines endothelin-1 regulation and quality of lung preservation for transplantation. Am. J. Respir. Cell. Mol. Biol., 2002, 26, 14-21.
62. Vos, I.H., Rabelink, T.J., Dorland, B., Loos, R., Van Middelaar, B., Grone, H.J., Joles, J.A. L-arginine supplementation improves function and reduces inflammation in renal allografts. J. Am. Soc. Nephrol., 2001, 12, 361-367.